{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-274378","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.825231+00:00","generated_at":"2026-05-16T22:24:28.192222+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Palvella Q3 net loss $11.3M; cash $63.6M; Phase 2/3 readouts on track for Dec 2025 and Q1 2026","bullets":["Net loss per share $1.03 (basic/diluted) vs $3.94 a year ago; R&D expense rose to $6.5M.","Cash & equivalents $63.6M, expected to fund operations into H2 2027.","Phase 2 TOIVA (cutaneous VMs) top-line results expected mid-December 2025.","Phase 3 SELVA (microcystic LMs) top-line results expected Q1 2026.","Expanded pipeline: angiokeratomas and QTORIN pitavastatin for DSAP; Phase 2 start H2 2026; David Osborne appointed CINO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-274378","json":"https://secwatch.observer/filing/0001193125-25-274378.json","markdown":"https://secwatch.observer/filing/0001193125-25-274378.md","text":"https://secwatch.observer/filing/0001193125-25-274378.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000119312525274378/0001193125-25-274378-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000119312525274378/pvla-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:24:28.192222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}